Related Experiment Video
Updated: Feb 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Biologic agents for severe asthma patients: clinical perspectives and implications
Massimo Caruso1, Jaymin Morjaria2, Rosalia Emma3
1Department of Clinical and Experimental Medicine, A.O.U. Policlinico - Vittorio Emanuele, Università degli Studi di Catania, Via S. Sofia, 78, 95123, Catania, Italy. mascaru@unict.it.
Severe asthma management is improving with biologic agents like omalizumab and mepolizumab. Future research aims to optimize their use through better understanding and predictive biomarkers for targeted asthma therapy.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Asthma is a chronic airway inflammatory disease.
- Current treatments are often insufficient for severe cases.
- Biologic therapies targeting molecular mediators have emerged.
Purpose of the Study:
- To review current biologic agents for severe asthma.
- To analyze their clinical application, benefits, and drawbacks.
- To identify knowledge gaps in their use.
Main Methods:
- Narrative review of existing literature.
- Focus on clinical application and evidence.
- Analysis of omalizumab and mepolizumab.
Main Results:
- Omalizumab is widely used in clinical practice.
- Mepolizumab shows emerging evidence for severe asthma.
- Gaps exist in understanding optimal application and predictive markers.
Conclusions:
- Biologic agents offer new avenues for severe asthma.
- Further research is needed to refine their use.
- Identifying predictive biomarkers is crucial for personalized asthma treatment.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

